Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

906.06
MXN
+2.56
(+0.28%)
34.20EPS
Feb 04Next Earn

Important Dates

Swedish Orphan Biovitrum AB's next confirmed earnings release is scheduled for February 4, 2027.

Earnings Date2/4/2027

Share Statistics

As of September 30, 2026, Swedish Orphan Biovitrum AB has 348.00M shares outstanding.

Shares Outstanding348.00M

Financial Position

As of September 30, 2026, Swedish Orphan Biovitrum AB maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Current Ratio0.99
Quick Ratio0.05
Debt / Equity35.56
Debt / EBITDA1.27

Financial Efficiency

MXN

These figures cover the twelve months ended September 30, 2026. The company generates approximately 30.58M in revenue per employee across its workforce of 1,888.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee30.58M
Employee Count1,888.00

Taxes

MXN

Over the twelve months ended September 30, 2026, Swedish Orphan Biovitrum AB recorded 3.03B in income tax expense. That works out to an effective tax rate of 20.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 14.99B, leaving 11.96B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax3.03B
Effective Tax Rate20.19

Stock Price Statistics

As of the close on November 12, 2026, Swedish Orphan Biovitrum AB's stock has gained approximately 182.20% over the past 52 weeks.

52-Week Price Change182.20%

Income Statement

MXN

Over the twelve months ended September 30, 2026, Swedish Orphan Biovitrum AB generated 57.73B in revenue and converted that into 11.96B in net income, yielding earnings per share of 34.20. EBITDA reached 22.90B, while operating income came in at 17.19B.

Revenue57.73B
Gross Profit44.73B
Operating Income17.19B
Pretax Income14.99B
Net Income11.96B
EBITDA22.90B
EBIT16.39B
Earnings Per Share (EPS)34.20

Balance Sheet

MXN

As of September 30, 2026, Swedish Orphan Biovitrum AB holds 1.81B in cash and equivalents against 29.17B in total debt, resulting in a net debt position of 26.69B. Total book value stands at 82.01B, with working capital of -303.36M providing operational flexibility.

Cash & Cash Equivalents1.81B
Total Debt29.17B
Net Debt26.69B
Equity (Book Value)82.01B
Book Value Per Share235.66
Working Capital-303.36M

Cash Flow

MXN

Swedish Orphan Biovitrum AB produced 14.25B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -2.50B in capital expenditures, free cash flow totaled 11.75B - equivalent to 33.92 per share.

Operating Cash Flow14.25B
Capital Expenditures-2.50B
Free Cash Flow11.75B
FCF Per Share33.92

Margins

Over the twelve months ended September 30, 2026, Swedish Orphan Biovitrum AB posted a gross margin of 77.48, reflecting its pricing power and cost economics. The operating margin of 29.78 and net profit margin of 20.73 provide insight into operational efficiency.

Gross Margin77.48
Operating Margin29.78
Pretax Margin25.97
Profit Margin20.73
EBITDA Margin39.67

Stock Splits

Swedish Orphan Biovitrum AB's most recent stock split took place on August 28, 2023.

Last Split Date8/28/2023